Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules 22/02/2020 Medications DUBLIN–(BUSINESS WIRE)–February 18, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) Read more